HCWB vs. SGTX, TTOO, LMNL, ENLV, CYAD, ALIM, RIGL, CNTX, PRQR, and SGMT
Should you be buying HCW Biologics stock or one of its competitors? The main competitors of HCW Biologics include Sigilon Therapeutics (SGTX), T2 Biosystems (TTOO), Liminal BioSciences (LMNL), Enlivex Therapeutics (ENLV), Celyad Oncology (CYAD), Alimera Sciences (ALIM), Rigel Pharmaceuticals (RIGL), Context Therapeutics (CNTX), ProQR Therapeutics (PRQR), and Sagimet Biosciences (SGMT). These companies are all part of the "medical" sector.
HCW Biologics (NASDAQ:HCWB) and Sigilon Therapeutics (NASDAQ:SGTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, community ranking, dividends and earnings.
Sigilon Therapeutics has a consensus target price of $21.00, suggesting a potential downside of 6.54%. Given Sigilon Therapeutics' higher possible upside, analysts plainly believe Sigilon Therapeutics is more favorable than HCW Biologics.
HCW Biologics has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, Sigilon Therapeutics has a beta of 4.12, indicating that its share price is 312% more volatile than the S&P 500.
In the previous week, HCW Biologics had 2 more articles in the media than Sigilon Therapeutics. MarketBeat recorded 2 mentions for HCW Biologics and 0 mentions for Sigilon Therapeutics. HCW Biologics' average media sentiment score of 1.59 beat Sigilon Therapeutics' score of 0.00 indicating that HCW Biologics is being referred to more favorably in the media.
Sigilon Therapeutics received 18 more outperform votes than HCW Biologics when rated by MarketBeat users. However, 100.00% of users gave HCW Biologics an outperform vote while only 58.54% of users gave Sigilon Therapeutics an outperform vote.
3.0% of HCW Biologics shares are owned by institutional investors. 49.9% of HCW Biologics shares are owned by insiders. Comparatively, 6.5% of Sigilon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
HCW Biologics has higher earnings, but lower revenue than Sigilon Therapeutics. Sigilon Therapeutics is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.
Sigilon Therapeutics has a net margin of -171.29% compared to HCW Biologics' net margin of -697.53%. Sigilon Therapeutics' return on equity of -83.07% beat HCW Biologics' return on equity.
Summary
HCW Biologics beats Sigilon Therapeutics on 9 of the 16 factors compared between the two stocks.
Get HCW Biologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HCWB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HCWB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HCW Biologics Competitors List
Related Companies and Tools
